86results about How to "Clear chemical structure" patented technology

The invention provides a sinomenine injection special for intravenous administration. The sinomenine injection is an injection which comprises 0.005-0.3wt% of sinomenine and an aqueous solvent for injection, or an injection which comprises sterile injection powder or lyophilized injection powder used for preparation just before injection to cause the sinomenine concentration to be 0.005-0.3wt% in the injection and the aqueous solvent for injection. The sinomenine injection of the invention is used for treating rheumatism, chronic pain and other chronic inflammatory diseases. Compared with other existing injection forms, the sinomenine injection special for intravenous injection has lower drug adverse reaction, and the clinical curative effect is obviously improved.

The invention discloses an active Ganoderma lucidum polysaccharide peptide reference substance, and a preparation method and application of the reference substance, and provides an active Ganoderma lucidum polysaccharide peptide reference substance for measuring and evaluating the quality of Ganoderma lucidum and Ganoderma lucidum products. The reference substance can correct the errors in polysaccharide measurement generated using glucose as the reference substance after addition of starch as an adjuvant during the deep processing process of Ganoderma lucidum. The preparation method uses Ganoderma lucidum as a raw material and comprises the steps of soaking in water, boiling, collecting an extractive solution, concentrating, centrifuging, dialyzing, entrapping polysaccharide protein GL-PP with an active macromolecular site, further carrying out ethanol gradient separation of the GL-PP, centrifuging, and collecting precipitates; and separately carrying out column separation, and selecting active polysaccharide peptide GL-PPS as the reference substance for detecting polysaccharide peptides, wherein the reference substance can be used for accurate measurement of the content of trace active polysaccharide peptides in a UV (ultraviolet) instrument. The pure product of the reference substance disclosed by the invention can be used for detecting the quality of Ganoderma lucidum products, and can eliminate the interference of starch and other adjuvants in the Ganoderma lucidum products, so as to improve the quality standards of Ganoderma lucidum products.

The invention provides a preparation method of a hydrogel scaffold for amplifying human iPS (induced pluripotent stem) cells without differentiating. The prepared hydrogel cell scaffold takes synthetic polymer hydrogel as a cell culture scaffold under conditions of not modifying any protein extracted from an animal body or relating to any trophocyte, and is an ideal biological material for safelyculturing human pluripotent stem cells with the advantages of definite chemical structure of synthetic polymer hydrogel, stable physicochemical performance, easiness in regulation and control, no foreign body infection, easiness in sterilization and low price. Therefore, a soft material culture system, which can safely, simply and conveniently amplify human iPS cells without differentiating, can be established.

The invention relates to application of sinomenine as a medicament for preventing and treating pulmonary interstitial fibrosis. The medicament is prepared by sinomenine or pharmaceutically acceptable salt thereof and other adjuvants, wherein sinomenine or pharmaceutically acceptable salt thereof serves as an activating agent. The routes of administration of the medicament include intravenous drip, intramuscular injection, oral administration, transdermal absorption, atomization inhalation and bronchoalveolar lavage. Experiments show that sinomenine does not have obvious difference with the dexamethasone control group in the effect on inhibiting formation of bleomycin-induced pulmonary fibrosis in mice and prove that sinomenine can alleviate pulmonary alveolitis and fibrosis degrees of themice with bleomycin-induced pulmonary fibrosis and the mechanisms are probably realized by inhibiting expressions of TGF (transforming growth factor)-beta1 and alpha-SMA (smooth muscle actin) and thecontent of HYP (hydroxyproline).

The invention relates to a multi-arm structure photoelectric-function material based on triindene elements, which is a multi-arm structure fluorenyl derivative using phenylcarbazole-modified triindene as the core and fluorene oligomers as the branch arms. The general formula of the multi-arm structure fluorenyl derivative is disclosed as Formula I in the specification, wherein R is a C1-C30 alkyl group; Ar is a conjugated-structure fluorescence chromophore selected from fluorene derivatives, such as alkyl fluorene, aryl fluorene and the like; X is a capping group selected from hydrogen; and n stands for the number of Ars, specifically a natural number between 1 and 3. The multi-arm structure photoelectric-function material based on triindene elements has excellent amorphous property, film-forming property and thermal stability; a conventional column chromatography method can be used for purification to obtain a high-chemical-purity material, and a simple solution processing method can be used for preparing an organic electronic thin-film device; and the multi-arm structure photoelectric-function material based on triindene elements can be widely used as a luminescent material in an organic luminescent device, especially a stable high-efficiency blue organic electroluminescent thin-film device.

The invention relates to a method for quickly separating and preparing high-purity deoxyrhapontin and rhapontin. The method comprises the following steps of: (1) cutting or grinding the dry root or rhizome of the wild or cultivated rhubarb plant to obtain the extraction raw material; (2) performing alcohol extraction and drying of the extraction raw material to obtain an extract; (3) mixing four solvents of methanol, water, n-butyl alcohol and chloroform; shaking, standing for layering and collecting the upper-phase solvent and the lower-phase solvent; and performing ultrasonic treatment of the upper-phase solvent and the lower-phase solvent to obtain a stationary phase and a mobile phase; (4) dissolving the extract in the mobile phase to obtain a sample injection solution; (5) sequentially pumping the stationary phase and the mobile phase into a separation tube of a high-speed counter-current chromatographic apparatus, and injecting the sample injection solution into a sample injection ring of the high-speed counter-current chromatographic apparatus; (6) collecting the effluent liquid A in the time range from 70min to 100min, and drying the effluent liquid A to obtain deoxyrhapontin; (7) reversely rotating the separation tube; and (8) collecting the effluent liquid B in the time range from 400min to 450min, and drying the effluent liquid B to obtain rhapontin. The method provided by the invention is simple to operate and facilitates the industrial production.

The present invention discloses one kind of rhubarb anthraquinone compound separated and extracted from rhubarb and with powerful SARS virus inhibiting effect. Extracorporeal experiment shows that the compound has SARS coronavirus 3C-like proteinase inhibiting rate over 85 % when the medicine dosage is 100 microgram / ml. In addition, the present invention has the features of clear medical speciality of rhubarb, rich medicine resource, clear rhubarb anthraquinone compound structure, determined acting mechanism and mature extraction process, and is significant in developing high efficiency and low toxicity SARS virus resisting medicine.

The invention discloses two steroids and a triterpenoid and an extraction method and application thereof, and belongs to the field of medicine. The compounds are novel steroids and a triterpenoid, andare identified by physicochemical constants and modern spectroscopy. The physicochemical properties and chemical structure are clarified, thus providing powerful reference data for further research and development and utilization of triterpenoid and steroid chemical components in lagerstroemia speciosa. The separation and purification method of the invention is simple, efficient and mild; meanwhile, the pharmacodynamic test shows that the two novel steroids provided by the invention have better in-vitro anti-inflammatory activity and have anti-inflammatory activity against BV-2 cells, and itindicates that the compounds and tautomers and pharmaceutically acceptable salts thereof have great potential as a novel anti-inflammatory or Alzheimer's disease drug, which lays the foundation for further development of the anti-inflammatory or Alzheimer's disease drug.

The invention discloses the effect target of a medicine for treating tumors and indications thereof. The medicine is extracted from tea leaves of which the safety is confirmed by eating for thousands of years. The medicine has a definite chemical structure, namely epigallocatechin gallate with the English name of (-)-Epigallocatechin gallate, EGCG for short. The research of the invention shows that the effect target of the medicine and a preparation thereof in cells is the NOTCH protein of people or animals. The medicine and the preparation thereof have the effect mechanism of suppressing the abnormal activation of an NOTCH signal. The medicine adapts to the treatment of tumors with abnormal NOTCH signals. Because the abnormity of the NOTCH signals nearly occurs in all tumor cells and the medicine and the preparation thereof also have higher safe dose, the medicine and the preparation thereof have extensive and definite market application prospect.

The invention relates to a preparation and verification method of a Chlorella protein molecule, which comprises the steps of: suspending Chlorella mud in pH 7.0 0.001mol / L phosphate buffer solution (PBS), and repeatedly freezing and thawing three times; ultrasonically crushing in an ice bath for 9min; centrifuging at the temperature of 4 DEG C and 12000r / min for 30min, collecting supernatant and adding ammonium sulfate with saturation degree of 30%; standing at the temperature of 4 DEG C for 24h, and centrifuging at the temperature of 4 DEG C and 12000r / min for 30min; and concentrating the supernatant with an ultrafiltration cup to 200mL, dissolving precipitate with little PBS, placing in a dialysis membrane, dialyzing in pH 7.0 0.001mol / L PBS under stirring for 2d, and embedding with polyethylene glycol-6000 to 60mL. By the adoption of the method to separate the purified protein molecule of Chlorella, the protein is released from the tissue or cell, the original native state is kept, and the activity is not lost, so that the specific chemical structure of the protein molecule can be accurately determined.

The invention discloses a Timicosin compound preparation and a preparation method and use thereof, which relate to the field of livestock breeding. The Timicosin compound preparation comprises the following components: Timicosin and Pidotimod. The invention also provides the preparation method and use of the Timicosin compound preparation. The Timicosin compound preparation provided by the invention is simple in composition and high in safety; and the Timicosin and Pidotimod in the compound preparation can produce a synergic effect in body, so that the Timicosin, at a lower use concentration, can reduce the number of the blue ear disease viruses in the bodies of newly borne piglets by inhibiting the blue ear disease virus content in the body of sows and thus improves the immunity in the bodies of the piglets and the indexes of the productivity of the piglets and reduce breeding benefit. The Timicosin compound preparation prepared by the invention can be used for breeding sows in a pregnant or lactation period. In addition, the preparation method provided by the invention is simple, and the prepared Timicosin compound preparation is stable.

The invention discloses an application of a morindae officinalis extract and morindae officinalis oligosaccharide pentasaccharide to preparation of a drug for treating myocardial ischemia and / or reperfusion injury and promoting therapeutic angiogenesis. The myocardial ischemia and reperfusion injury belong to secondary injury brought to an organism when the hemoperfusion of myocardium is stopped or poor, i.e., after the myocardium is subjected to ischemia, hypoxia injury, circulation reinstitution and blood supply recovery. The morindae officinalis extract and the morindae officinalis oligosaccharide pentasaccharide both play a role in protecting an in-vivo rat myocardial ischemia reperfusion injury model and an in-vitro purification cultured neonatal rat myocardial cell hypoxia / reoxygenation injury model, and can be used for remarkably reducing the myocardial infarction area and the incidence rate of reperfusion arrhythmias, effectively protecting the form of a myocardial cell and relieving the injury of hypoxia / reoxygenation to the myocardial cell. The therapeutic angiogenesis promotion means that the aims of recovering the blood supply of ischemic myocardium and improving the heart function are achieved through increasing the functional coronary artery branch or side branch under the irritation actions of some methods, including the therapeutic actions of some drugs.

The invention discloses an application of a Morindae officinalis extract product and Morindae officinalis oligosaccharide 6 glycan in the preparation of medicines for resisting myocardial ischemia and / or reperfusion injury and promoting therapeutic angiogenesis. The myocardial ischemia and reperfusion injury are body injuries caused by the afresh circulation establishment and the blood supply recovery during the stopping or abnormality of the myocardial blood perfusion, like ischemic and anoxic injuries. The Morindae officinalis oligosaccharide 6 glycan has a protect effect on an in-vivo rat myocardial ischemia reperfusion injury model and an in-vitro purify-cultured mouse myocardial cell reoxygenation injury model, can substantially reduces the myocardial infarction area, can mitigate the reperfusion arrhythmia, can effectively protect the form of myocardial cells, and can mitigate the injuries of anoxic reoxygenation to the myocardial cells. The therapeutic angiogenesis promotion is characterized in that the ischemic myocardial blood supply recovery and the cardiac function improvement are realized by increasing the functional coronary arterial tree or coronary collateral through some irradiations comprising the treatment effects of some medicines.

The invention relates to an organic solar cell material and a preparation method thereof, particularly a novel organic solar cell material based on thiophene-diazosulfide p-n structure and a preparation method thereof. The quantities and contents of the p-type electron donating primitive thiophene and n-type electron receiving primitive diazosulfide are regulated to precisely regulate the band gap of the target material, and the alkyl chain is modified to implement solubility in a polar solvent and application in the field of organic photoelectricity. The structure is disclosed as Formula I. According to the material provided by the invention, Suzuki reaction is utilized to synthesize the monomer, and the material is simple in synthesis technique, easy for mass production and easy to purify. The material has favorable spectrum heat stability, amorphous film-forming stability and narrow optical energy gap, can absorb sunlight within a wider wave spectrum range, and can be used in organic solar cell devices as an active material.

The invention relates to a healthcare oral liquid with a good curative effect and no side effect. Every 300kg of the oral liquid contains components of, by weight: 50-55kg of kirilow rhodiola root and rhizome, 20-30kg of red ginseng, 20-30kg of Mongolian milkvetch root, 15-22kg of prepared rhizome of rehmannia, 8-12kg of licorice root, 8-12kg of medlar, 20-25kg of mythic fungus, 60-80kg of honey, and balance of purified water.

The invention provides a donor-acceptor-donor-acceptor-donor oligothiophene derivative taking dithienopyrrole as a molecular center. The chemical structural formula of the derivative is shown in formula I in the description, synthesis comprises the steps that 2,6-di(trimethyl-tin)-N-iso-octane-dithieno[3,2-b:2',3'-d]pyrrole and 4,7-dibromine-[1,2,5]thiadiazole[3,4-c]pyridine react to synthesize an intermediate (2,6-2{(4-(7-bromine-[1,2,5]thiadiazole[3,4-c]pyridine)}-N-iso-octane-dithieno[3,2-b:2',3'-d]pyrrole); and then the (2,6-2{(4-(7-bromine-[1,2,5]thiadiazole[3,4-c]pyridine)}-N-iso-octane-dithieno[3,2-b:2',3'-d]pyrrole) reacts with 2-(trimethyl-tin)-5-(4-n-hexylphenyl)thiophene to obtain the target oligothiophene derivative. The oligothiophene derivative has a narrow band gap, a lowHOMO energy level, good solubility and film formation, and is expected to be used as an organic semiconductor material in the preparation of organic thin film field effect transistors, organic light emitting diodes and organic solar cell devices.

The invention relates to a tri-indene-pyrene derivative blue-light emitting material, and a preparation method and application thereof. The material is a polysubstituted compound taking tri-indene as a core and seals the end by pyrene; the general formula structure is shown in the specification, wherein R is alkyl of C1-C12; the material has the characteristics that the material is simple in synthetic process, easy for volume production and easy to purify, and high chemical purity can be obtained by a simple column chromatography method; and the material displays excellent luminescence property, thermal stability, amorphous performance and spectral thermal stability when being applied as a luminescent film material, and has important application potential in the fields such organic electroluminescence and organic laser. In particular, an organic electroluminescence device using the material as the luminescent layer has efficient electroluminescent blue emission, improved color purity and excellent spectrum and apparatus stability; and the material is a blue organic electroluminescent material with practical prospect.

The invention relates to a narrow-energy-gap organic solar cell material and a preparation method thereof, particularly a novel narrow-energy-gap organic solar cell material based on thiophene-diazosulfide p-n structure and a preparation method thereof. The quantities and contents of the p-type electron donating primitive thiophene and n-type electron receiving primitive diazosulfide are regulated to precisely regulate the band gap of the target material, and the alkyl chain is modified to implement solubility in a polar solvent and application in the field of organic photoelectricity. The structure is disclosed as Formula I. According to the material provided by the invention, Suzuki reaction is utilized to synthesize the monomer, and the material is simple in synthesis technique, easy for mass production and easy to purify. The material has favorable spectrum heat stability, amorphous film-forming stability and narrow optical energy gap, can absorb sunlight within a wider wave spectrum range, and can be used in organic solar cell devices as an active material.

The invention provides a polypeptide derivative, nanofiber and application of the nanofiber. The polypeptide derivative can effectively simulate bioactivity of IGF-1 protein and can be used as a substitute of the IGF-1 protein, the production process is simpler, the yield is higher, and the polypeptide derivative has better storage stability. The sequence of the polypeptide derivative is X-Phe-Phe-Gly-Ser-Ser-Ser-Arg, wherein an end group X is Nap or Npx, Phe is an L configuration or a D configuration simultaneously, and the rest are L configurations. A water mixture of the polypeptide derivative forms the nanofiber by a heating and cooling method. The polypeptide derivative can bind with an IGF-1 protein receptor and can be used for treating muscle atrophy and atherosclerosis.

The invention relates to a blue-ray material, in particular to an electron withdrawing end group modified fluorene-pyrene derivative blue-ray material which is a multi-branch fluorenyl derivative with pyrene serving as the core and electron withdrawing end group modified oligomer fluorene serving as branches. The structural general formula is shown in the formula I, wherein R is C1-C20 alkyl, X is an end group selected from one of the groups shown as follows, and n is the number of 9,9-dialkyl-substituted fluorene and is specifically 1, 2 and 3. The electron withdrawing end group modified fluorene-pyrene derivative blue-ray material shows excellent light emission performance, thermal stability, amorphous performance, film forming stability and spectrum thermal stability, and can be used as a luminescent material to be widely applied to organic luminescent devices, especially stable and efficient blue-ray organic electroluminescent devices.

The invention discloses an application of mesaconine. The application is the application of mesaconine or pharmaceutically acceptable salts, esters or solvates of mesaconine in preparation of drugs orhealth care products for preventing and / or treating myocardial fibrosis. Mesaconine can effectively prevent and / or treat myocardial fibrosis and chronic heart failure or cardiac remodeling caused bymyocardial fibrosis.

An inner scaffold with the coated medicine for preventing and treating re-stenosis of cavity tract is composed of the main body of scaffold and the coated medicine including curcumin. It features that said coated medicine can be slowly released to suppress the reproduction of smooth muscle cells and the synthesis of extracellular matrix and resist blood coagulation and inflammation. It is especially for the plastic operation of transcortical arteria coronaria.

The invention discloses a chemically modified thymopentin and a synthetic method thereof. The structure of the chemically modified thymopentin is shown as follows: A-Arg-Lys-Asp-Val-Try-OH or H-Arg-Lys(A)-Asp-Val-Try-OH. The A is a micromolecule ligand. The micromolecule ligand is an aliphatic acid bonding in affinity with human serum albumin, or is a maleimide derivative coupled with free sulfydryl of human serum albumin. The chemically modified thymopentin has characteristics of precision modification sites, a definite chemical structure and a simple and concise synthetic process. The chemically modified thymopentin after being injected intravenously bonds immediately with the serum albumin of the human body and adopts the serum albumin of the human body as a controlled-release vector, thus prolonging the half-life period largely, and significantly prolonging the time of duration of the effective medicine concentration. The bioavailability is high.

The invention discloses a streblus indica bur extract with hepatitis B virus resistance and a relative extraction method, wherein the basic formula of the extract is C3-C6-C6-C3 as streblus indica bur lignan compound. And the extraction method comprises breaking streblus indica bur, extracting via alcohol, methanol or water, extracting concentrated solution, extracting the concentrated solution via ligarine, ether, acetic ester and butanol respectively, processing silica gel column chromatography on the extracts, gradually eluting via at least one of ligarine, chloroform, acetic ester, ether and methanol, and obtaining streblus indica bur lignan compound. When the drug dosage is 100ug / ml, the inhibition rate on the HBsAg expression of hepatitis B virus cell line reaches at least 76.6% in vitro experiment, and when the drug dosage is 100ug / ml, the inhibition rate on the HbeAg expression reaches at least 81.6%. The invention discloses a new Chinese medicine source with hepatitis B virus resistance, with simple and mature extraction method and high value for developing high-effect low-toxin hepatitis B virus resistant drug.

The invention discloses a formula of an anti-oxidation health product taking L-Se-methylselenocysteine as a main raw material. The anti-oxidation health product comprises the following main effect components: vitamin E, vitamin C, a grape seed extract, lycopene and tea polyphenol, and belongs to the technical field of functional health food. According to the formula, L-se-methylselenocysteine which is definite in chemical structure, low in toxicity and high in bioactivity is used as the main effect component; under the synergistic effect between L-se-methylselenocysteine and the vitamin E, the vitamin C, the grape seed extract, the lycopene and the tea polyphenol, the anti-oxidation function of the health product can be developed to the maximum extent. The health product fills the blank of an L-Se-methylselenocysteine product in the health food market, and the synergistic effect among all the compatible effect components is fully used; the anti-oxidation health product has the effects of resisting oxidation, clearing away free radicals, preventing aging of organs and delaying aging.

The invention provides a large yellow tea polysaccharide with anti-inflammatory activity, a preparation method and application of the large yellow tea polysaccharide and an anti-inflammatory pharmaceutical composition, and belongs to the technical field of application of active substances of large yellow tea. The large yellow tea polysaccharide with the anti-inflammatory activity is novel in structure, has a definite chemical structure, is uniform in composition, has an obvious anti-inflammatory function, can remarkably reduce expression of inflammatory factors in bone marrow-derived macrophages caused by lipopolysaccharide, and has no toxic or side effect on normal macrophages. As the polysaccharide with natural anti-inflammatory activity, the problem that the Huangdan tea lacks an active component with a single composition and a clear structure in the aspect of research and development of new anti-inflammatory drugs is solved, and a reliable material basis is laid for research on the structure-function relationship of the anti-inflammatory action of the Huangdan tea polysaccharide and research and development of the anti-inflammatory drugs.

The invention discloses semi-aromatic sulfonated polyether ketone for a proton exchange membrane material, and a preparation method thereof. The preparation method comprises the following steps: adding and dissolving aromatic sulfonated monomers and aliphatic dicarboxylic acid in Eaton reagent and mixing evenly; reacting for 2-24 hours at the temperature of 20-80 DEG C to obtain a solution; mixing the solution with distilled water to obtain flocculent solid precipitates; washing the flocculent solid precipitates with distilled water to remove inorganic compounds, and performing drying to obtain the semi-aromatic sulfonated polyether ketone. Due to the introduction of aliphatic chains, melt pouring membrane formation can be realized on the premise that the material using properties are satisfied, and the simplified technology and the excellent repeatability of the semi-aromatic sulfonated polyether ketone are beneficial to large-area preparation of membrane materials with uniform structures.

The invention relates to selenium-rich nutrition recombination rice. The nutrition rice is prepared from the following raw materials in parts by mass: 40-60 parts of selenium-rich corn meal, 40-60 parts of high-selenium-rich rice bran powder, 1-5 parts of high-selenium-rich volvariella volvacea powder, 1-10 parts of black sesame seed powder, 1-10 parts of soybean protein isolate and L-selenium-methyl selenocysteine. The raw materials are sufficiently mixed and then are blended with a proper amount of water; low-temperature controlled gelatinization granulation by a twin screw extruder and drying are performed to obtain recombinant nutrition pre-mixed artificial rice. By mixing the selenium-rich nutrition recombination pre-mixed rice prepared by the technology with common rice according toa ratio of 1 to 4, a product meeting the requirement on the selenium content of selenium-rich rice and having high absorption rate, metabolic rate and utilization rate can be prepared. The invention effectively solves the problems that the country has limited resources in selenium-rich regions, the raw materials of natural selenium-rich food are of excessive difference in selenium content and someof the food raw materials contain too much selenium; meanwhile, the rice bran byproduct in the processing of selenium-rich rice is scientifically utilized.